| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.5 |
| Net income | -11.5 | -35.9 |
| EPS (diluted, $ a share) | $-0.38 | $-1.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RNAC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cartesian Therapeutics, Inc.: key numbers
- Share price
- $6.08Close, Nov 16
- Market cap
- $185M
- Shares outstanding
- 30.5MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cartesian Therapeutics, Inc.
All →Cartesian Therapeutics Financial Results
Cartesian Therapeutics reported Q3 2026 financial results, ending the period with $124.7 million in cash to support operations into 2028. The company is advancing its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis with data expected in Q1 2027 and a BLA filing planned for mid-2027.
- Term
- Q3 2026
“With Phase 3 AURORA data expected in the first quarter of 2027, our focus this quarter remains on execution, both in the clinic and in preparing the organization for a commercial launch. Ahead of our anticipated BLA submission in mid-2027, we have expanded our medical affairs and commercial teams to drive launch readiness.”
Carsten Brunn, Ph.D., President and Chief Executive Officer
Cartesian Therapeutics Clinical Trial Data
Cartesian Therapeutics announced positive 12-month retreatment data from its Phase 2 trial of Descartes-08 in patients with myasthenia gravis (MG). The data showed that patients who were retreated after symptom recurrence experienced deep and durable responses, with a mean MG-ADL score reduction of 6.6 points at 12 months and no new safety signals. Topline data from the Phase 3 AURORA trial is expected in the first quarter of 2027.